含有帕克利塔塞尔的,具有高合体稳定性,持续的,对pH响应的释放和对肺癌A549细胞系的强有力的抗癌作用的化碳酸石墨烯氧化物
Athina Angelopoulou1, Myria Papachristodoulou1, Efstathia Voulgari1
1Department of Pharmacy, Medical School, University of Patras, 26504 Patras, Greece.
Pharmaceutics
|November 27, 2024
概括
聚乙烯糖醇 (PEG) 功能化石墨烯氧化物 (GO) 纳米颗粒显示出改善的生物相容性和稳定性,用于癌症药物输送. 携带帕克利塔塞尔 (PCT) 的PEG-GO纳米颗粒在肺癌细胞中表现出与自由PCT相比增强的抗癌活性.
科学领域:
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
- 纳米技术纳米技术
背景情况:
- 石墨烯氧化物 (GO) 对癌症治疗有希望,但面临生物安全和稳定性挑战.
- 聚乙烯甘醇 (PEG) 功能化解决了这些问题,提高了GO在生物环境中的生物相容性和稳定性.
研究的目的:
- 为了评估碳氧化,纳米化GO (nCGO) 作为帕克利塔塞尔 (PCT) 载体.
- 调查PEG特征对nCGO属性和PCT输送的影响.
- 在A549肺癌细胞中评估优化PEG-nCGO/PCT配方的抗癌疗效.
主要方法:
- 合成和表征PEGylated nCGO纳米粒子.
- 研究了PEG链长度和分支对粒子大小,表面电荷和体稳定性的影响.
- 评估PCT负荷,不同pH值的释放动力学和血液溶解潜力.
- 在A549细胞中评估了体外抗癌活性,包括细胞毒性和亡诱导.
主要成果:
- PEGylation 降低了粒子大小和增加了表面电荷,增强了体稳定性并减少了溶血效应.
- PEG特征影响PCT负载,具有更高的分子量和分支减少药物负载.
- 在酸性pH (6.0) 与生理pH (7.4) 相比,观察到PCT释放的增加.
- 随着时间的推移,PEG-nCGO/PCT显示了细胞毒性和亡诱导的增加,超过了24小时和48小时的自由PCT.
结论:
- 基化nCGO纳米颗粒为药物输送提供了更好的生物相容性和稳定性.
- PEG-nCGO/PCT配方表现出增强的抗癌活性,这表明纳米医学中临床应用的潜力.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K


